Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

NCT04882735 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor's decision to cancel study

Conditions

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Interventions

DRUG: Acoramidis

Sponsor

Eidos Therapeutics, a BridgeBio company